Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Insulet Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $9.3B |
|---|
| Revenue (ttm) | 3.1B |
|---|
| Net income (ttm) | 375.3M |
|---|
| EPS (ttm) | $5.30 |
|---|
| Shares out | 69.4M |
|---|
| P/E (trailing) | 28.1x |
|---|
| P/E (forward) | 55.0x |
|---|
| Volume | 686,221 |
|---|
| Beta | 1.10 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $1.04B | $1.06B | $1.70B | $2.07B | $2.71B | +27.0% |
| Gross profit | $752.1M | $805.6M | $1.16B | $1.45B | $1.94B | +26.7% |
| Operating income | $126.0M | $37.6M | $220.1M | $308.9M | $473.8M | +39.3% |
| Net income | $16.8M | $4.6M | $206.3M | $418.3M | $247.1M | +95.8% |
| EPS (diluted) | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 | +95.1% |
| EBITDA | $139.6M | $109.0M | $323.6M | $423.7M | $509.6M | +38.2% |
| R&D | $160.1M | $180.2M | $205.0M | $219.6M | $301.1M | +17.1% |
| SG&A | $466.0M | $587.8M | $734.8M | $917.2M | $1.17B | +25.7% |
Recent company headlines from major financial publishers.
The modal expected path reflects consensus-aligned execution: FY2026 revenue of $3,287.08M (21.38% growth) and FY2027 revenue of $3,735.00M (13.63% growth), guided by mid-teens exit growth. Operating margins expand ~100 basis points annually from 17.5% in FY2025 to 22.5% by FY2030, supporting diluted EPS of $6.51 in FY2026 and $7.73 in FY2027, yielding our house Fair value of $164.82.
Accelerated adoption of Omnipod 5 across intensive and basal Type 2 diabetes segments combines with rapid international expansion, driving consolidated top-line growth above 25% annually. Automated manufacturing lines achieve optimal yield efficiencies, expanding operating margins beyond 24% and compounding diluted EPS above 25% annually toward our high-case valuation of $210.43,.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 8.5% | $171 | $177 | $184 | $193 | $203 |
| 9.0% | $163 | $168 | $174 | $181 | $189 |
| 9.5% | $156 | $160 | $165 | $171 | $177 |
| 10.0% | $149 | $153 | $157 | $162 | $168 |
| 10.5% | $143 | $147 | $150 | $154 | $159 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
